CarlbergDepartment of Public Health and Clinical MedicineUniversity HospitalBoDepartment of Public Health and Clinical MedicineUniversity HospitalLancetCarlberg B. Time to lower treatment BP targets for hypertension? Lancet 2009;374:503-4.Carlberg B. Time to lower treatment BP target for hypertension. ...
Therefore, attaining very low BP levels or having poorly controlled, elevated BP levels both appear to be harmful in patients receiving treatment for hypertension. "Whereas current US guidelines emphasize the upper limits of therapeutic goals, the potential dangers of overtreatment may need to be cons...
A disrupted lifestyle can interfere with mood stability in bipolar disorder. Here’s how to start crafting a calmer life for better symptom control. When it comes to a bipolar diagnosis, treatment, and symptom management, we often hear references to the “journey” and “process.” Much like...
In the absence of an approved disease-modifying treatment, symptomatic treatment is the mainstay of management. The purpose of this review is to present an overview of the management of these complex disorders, with a particular focus on a holistic and multidisciplinary approach. Recent Findings In...
Participants will receive an intravenous infusion of aducanumab at 10 mg/kg monthly for 2 years, and eligible participants will continue to receive the infusion for another 52 weeks during the long-term extended treatment period. The primary outcomes are safety and tolerability, and the efficacy ...
[1]. Depression has become a highly concerning public health issue on an international scale. However, due to the complex pathological mechanisms of neurological diseases, frontline health care professionals often face clinical difficulties such as complex adverse reactions and low treatment efficacy. As...
Orally for treatment (in combination with fluoxetine) of acute depressive episodes associated with bipolar I disorder. Olanzapine monotherapy is not indicated for treatment of depressive episodes associated with bipolar I disorder.IM (as short-acting olanzapine) for management of acute agitation in ...
One hundred and fifteen healthy participants (69 female) completed this double-blind, placebo-controlled, randomized clinical trial in which participants were randomly assigned to receive either a single infusion of low-dose endotoxin (derived from Escherichia coli; 0.8 ng/kg of body weight) or ...
This may give insights into whether there is an optimal developmental window for ASO treatment to rescue these cellular phenotypes. Our proof-of-concept study, which includes a combination of in vitro and in vivo studies with human patient-derived, three-dimensional, multicellular models, illustrates...
Placebo effects are a well-established phenomenon in the treatment of depression. However, the mechanism underlying these effects are not fully understood. Treatment expectations are considered one explanation for why placebos work. Treatment expectation